X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - HEALTHTECHZONE.COM - IT Professionals - 13/Dec 23:15

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

Articles similaires

Sorry! Image not available at this time

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous Cell Carcinoma

drugs.com - 13/Dec 21:12

WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), today announced that the U.S. Food and...

Sorry! Image not available at this time

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

healthtechzone.com - 20/Dec 03:47

Sorry! Image not available at this time

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

drugs.com - 10/Dec 01:12

LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative...

Sorry! Image not available at this time

FDA pre-approval inspection of EBR’s WiSE CRT system set for early January

stockhead.com.au - 19/Dec 22:55

The US FDA has scheduled a pre-approval inspection of EBR System’s WiSE CRT System for the week of January 6, ...

Sorry! Image not available at this time

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

zacks.com - 11/Dec 15:02

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's...

Sorry! Image not available at this time

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

drugs.com - 19/Dec 01:12

TARRYTOWN, N.Y., December 19, 2024 – Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and...

Sorry! Image not available at this time

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

drugs.com - 19/Dec 01:12

TARRYTOWN, N.Y., December 19, 2024 – Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and...

Sorry! Image not available at this time

MBOT Stock Gains Following FDA Submission of the LIBERTY System

zacks.com - 12/Dec 16:51

Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.

Sorry! Image not available at this time

FDA Approved Drug Products Approval List November 2024

pharmabiz.com - 18/Dec 12:18

FDA Approved Drug Products Approval List November 2024

Sorry! Image not available at this time

ZBH Stock Might Rise Following FDA Nod for OsseoFit

zacks.com - 16/Dec 12:35

Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.

Les derniers communiqués